Lung Cancer ScreeningC-Raven LDCTNCT07819318
C-Raven LDCT: Lung Cancer Screening Intervention
A study testing Video/Brochure and Video/Brochure/Follow-up Call in people with Lung Cancer Screening, run by Johns Hopkins University.
Trial summary
This study is a three-arm, randomized controlled pilot of a lung cancer screening intervention. The investigators will recruit participants ages 50-80 who are likely to meet lung cancer screening guidelines. Read more about this study
- Who is it for?
- Ages 50 to 80 years
- Conditions the study is for
- Lung Cancer Screening
- What is being tested?
- Video/Brochure and Video/Brochure/Follow-up Call
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- 15 Oct 2026to 30 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Existing record within the Johns Hopkins medical system
- Age 50-80
- Current tobacco use OR cessation within the past 15 years
- 20-pack year history of smoking
- No chest CT imaging within the past 18 months
- English speaking
- Willing to complete the study procedures, which include questionnaires and possibly a follow-up call
Who cannot join
- Not meeting eligibility criteria
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: C-Raven LDCT: Pilot Randomized Control Trial (RCT) of a Lung Cancer Screening Intervention
This study is a three-arm, randomized controlled pilot of a lung cancer screening intervention. The investigators will recruit participants ages 50-80 who are likely to meet lung cancer screening guidelines. After eligibility screening, participants will be randomized to one of three educational interventions regarding lung cancer. Lung cancer screening outcomes will be assessed.
Read the detailed description
Smoking is associated with a dramatically increased risk of lung cancer, with rates 10-40 times higher among those who smoke than among those who do not smoke, with smoking accounting for about 85-90% of all lung cancer cases. Screening for lung cancer with low-dose computed tomography (LDCT) has been shown to significantly reduce lung cancer mortality in high-risk populations. Lung cancer screening with annual LDCT is therefore recommended by the US Preventive Services Task Force (USPSTF) for all adults aged 50 to 80 years with a 20 pack-year history of smoking who currently smoke or have quit within the past 15 years. However, in a nationwide study of individuals eligible for lung cancer screening in 2022, only 18% were up-to-date with the recommended screening.
The investigators propose a three-arm, randomized controlled pilot of a lung cancer screening intervention. Recruitment will be carried out primarily through the electronic health record, with invitations sent to patients aged 50-80 who have a documented history of smoking but no chest CT on file within the past 18 months. The investigators will also partner with community organizations such as senior centers and churches to distribute information about the study.
Potential participants will be screened for eligibility for lung cancer screening. If eligible, the participants will undergo a consent process, complete baseline surveys (demographics, etc.), and be randomized to one of the following three study conditions:
- Notification of eligibility for lung cancer screening with a recommendation to discuss with the participant's health care provider
- Animated video on shared decision-making for LDCT with accompanying guide, offered as a downloadable PDF or mailed hard copy, per individual preference
- Video and guide as in (b), plus a one-on-one call with a community health worker (CHW), 1-2 weeks after viewing the materials
Three months after receiving the intervention, follow-up surveys will be sent to assess attitudes toward and completion of lung cancer screening.
- Conditions
- Lung Cancer Screening
- Being tested
- Video/Brochure, Video/Brochure/Follow-up Call
- Keywords
- tobacco, smoking, lung cancer, cancer screening
- Medical subject headings
- Smoking, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Video/BrochureBehavioural
Brief animated video that covers the basics of lung cancer screening and shows shared decision-making. An accompanying brochure uses images and information from the video to reinforce concepts (delivered via PDF or mail, per participant preference).
Video/Brochure/Follow-up CallBehavioural
Brief animated video that covers the basics of lung cancer screening and shows shared decision-making. An accompanying brochure uses images and information from the video to reinforce concepts (delivered via PDF or mail, per participant preference). A follow-up call with a community outreach specialist/community health worker is made 1-2 weeks after the initial intervention to check in on participant plans regarding lung cancer screening and to assist with any barriers.
| Study group | Role | What they receive |
|---|---|---|
| Notification of Eligibility | No intervention | Participants receive notification of eligibility for lung cancer screening with a recommendation to discuss with their health care provider |
| Video/Brochure | Experimental | Participants receive an animated video with accompanying guide. Receives: Behavioral: Video/Brochure |
| Video/Brochure/Follow-up Call | Experimental | Participants receive an animated video video, an accompanying guide, and a call with a community outreach specialist/community health worker. Receives: Behavioral: Video/Brochure/Follow-up Call |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Completion of Lung Cancer Screening
Self-reported completion of low dose chest CT for lung cancer screening during the study follow-up period
Measured: 3 months
Secondary outcomes (2)
Number of Participants with Clinician Discussion on Lung Cancer Screening
Self-reported conversation with clinician about lung cancer screening during the study follow-up period
Measured: 3 months
Number of Participants with Change in Intent to obtain lung cancer screening
Change in intent to obtain lung cancer screening
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2026
- Study start15 Oct 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer ScreeningStudies of the same condition, open and under way.
- More trials run by Johns Hopkins UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins University
- Sponsor type
- University, hospital or other
- Collaborators
- Maryland Cigarette Restitution Fund
- Responsible party
- Sponsor
- Investigators
- Alejandra Ellison-Barnes, MD, MPH, Principal investigator, Johns Hopkins University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07819318
- Sponsor's protocol ID
- IRB00560126
- Other IDs
- PHPA-3928/M00B7600145
- Acronym
- C-Raven LDCT
- Status last verified
- Sep 2026
- First submitted
- 8 Sep 2026
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- C-Raven LDCT: Pilot Randomized Control Trial (RCT) of a Lung Cancer Screening Intervention
- ClinicalTrials.gov ID
- NCT07819318
- Acronym / sponsor ID
- C-Raven LDCT / IRB00560126
- Conditions
- Lung Cancer Screening
- Keywords
- tobacco, smoking, lung cancer, cancer screening
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Johns Hopkins UniversityUniversity, hospital or other
- Collaborators
- Maryland Cigarette Restitution Fund
- Study start
- 15 Oct 2026 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Aug 2027 (estimated)
- First posted
- 14 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a three-arm, randomized controlled pilot of a lung cancer screening intervention. The investigators will recruit participants ages 50-80 who are likely to meet lung cancer screening guidelines. After eligibility screening, participants will be randomized to one of three educational interventions regarding lung cancer. Lung cancer screening outcomes will be assessed.
Detailed description
Smoking is associated with a dramatically increased risk of lung cancer, with rates 10-40 times higher among those who smoke than among those who do not smoke, with smoking accounting for about 85-90% of all lung cancer cases. Screening for lung cancer with low-dose computed tomography (LDCT) has been shown to significantly reduce lung cancer mortality in high-risk populations. Lung cancer screening with annual LDCT is therefore recommended by the US Preventive Services Task Force (USPSTF) for all adults aged 50 to 80 years with a 20 pack-year history of smoking who currently smoke or have quit within the past 15 years. However, in a nationwide study of individuals eligible for lung cancer screening in 2022, only 18% were up-to-date with the recommended screening.
The investigators propose a three-arm, randomized controlled pilot of a lung cancer screening intervention. Recruitment will be carried out primarily through the electronic health record, with invitations sent to patients aged 50-80 who have a documented history of smoking but no chest CT on file within the past 18 months. The investigators will also partner with community organizations such as senior centers and churches to distribute information about the study.
Potential participants will be screened for eligibility for lung cancer screening. If eligible, the participants will undergo a consent process, complete baseline surveys (demographics, etc.), and be randomized to one of the following three study conditions:
- Notification of eligibility for lung cancer screening with a recommendation to discuss with the participant's health care provider
- Animated video on shared decision-making for LDCT with accompanying guide, offered as a downloadable PDF or mailed hard copy, per individual preference
- Video and guide as in (b), plus a one-on-one call with a community health worker (CHW), 1-2 weeks after viewing the materials
Three months after receiving the intervention, follow-up surveys will be sent to assess attitudes toward and completion of lung cancer screening.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Notification of Eligibility | No intervention | –Participants receive notification of eligibility for lung cancer screening with a recommendation to discuss with their health care provider |
| Video/Brochure | Experimental | Behavioral: Video/BrochureParticipants receive an animated video with accompanying guide. |
| Video/Brochure/Follow-up Call | Experimental | Behavioral: Video/Brochure/Follow-up CallParticipants receive an animated video video, an accompanying guide, and a call with a community outreach specialist/community health worker. |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Existing record within the Johns Hopkins medical system
- Age 50-80
- Current tobacco use OR cessation within the past 15 years
- 20-pack year history of smoking
- No chest CT imaging within the past 18 months
Key exclusion criteria (1 listed)
- Not meeting eligibility criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Video/BrochureBrief animated video that covers the basics of lung cancer screening and shows shared decision-making. An accompanying brochure uses images and information from the video to reinforce concepts (delivered via PDF or mail, per participant preference). | Behavioural | Video/Brochure |
| Video/Brochure/Follow-up CallBrief animated video that covers the basics of lung cancer screening and shows shared decision-making. An accompanying brochure uses images and information from the video to reinforce concepts (delivered via PDF or mail, per participant preference). A follow-up call with a community outreach specialist/community health worker is made 1-2 weeks after the initial intervention to check in on participant plans regarding lung cancer screening and to assist with any barriers. | Behavioural | Video/Brochure/Follow-up Call |
Primary outcome
Number of Participants with Completion of Lung Cancer Screening
Time frame: 3 months
Self-reported completion of low dose chest CT for lung cancer screening during the study follow-up period
2 secondary outcomes
Number of Participants with Clinician Discussion on Lung Cancer Screening
Time frame: 3 months
Number of Participants with Change in Intent to obtain lung cancer screening
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer Screening
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Not yet recruiting
Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers
Lung Cancer (Diagnosis), Smoking Cessation
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Alejandra Ellison-Barnes, MD, MPH principal investigator
Johns Hopkins University
Questions about this trial
What is this clinical trial studying?
A study testing Video/Brochure and Video/Brochure/Follow-up Call in people with Lung Cancer Screening, run by Johns Hopkins University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alejandra Ellison-Barnes, MD, MPH (410-955-5000, aelliso6@jhmi.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Completion of Lung Cancer Screening (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.